TUDCA (tauroursodeoxycholic acid) is best known for liver and neuroprotective research, but a separate line of preclinical work has looked at what it does in the kidneys. Because TUDCA works partly by reducing endoplasmic reticulum (ER) stress — a mechanism implicated in several kidney diseases — researchers have tested it in animal models of acute kidney injury, diabetic kidney disease, and salt-induced renal damage.
This article covers what that research actually shows, and is direct about an important limitation: essentially all of it is in animals or cultured cells, not human patients.
Key Takeaways
- In a rat model of ischemia-reperfusion acute kidney injury, TUDCA reduced kidney damage by inhibiting ER stress pathways in kidney tissue.[1]
- A separate rat and cell-culture study found TUDCA prevented acute kidney injury by inhibiting the mitochondrial apoptosis (cell death) pathway and supporting cell survival signaling.[2]
- In diabetic (db/db) mice, eight weeks of TUDCA treatment reduced albuminuria and kidney tissue damage, associated with lower ER stress markers in the kidney.[3]
- None of this research has been replicated in human clinical trials — there is no published RCT testing oral TUDCA supplementation for kidney protection or chronic kidney disease in people.
- Anyone with existing kidney disease or reduced kidney function should not interpret animal-model results as a reason to self-supplement without medical guidance; kidney disease management requires individualized clinical care.
Why Researchers Looked at TUDCA and the Kidneys
ER stress — a cellular state where the endoplasmic reticulum accumulates misfolded proteins faster than it can process them — is now understood to play a role in several kidney injury pathways, including acute kidney injury from reduced blood flow, diabetic nephropathy, and fibrosis-driven chronic kidney disease. TUDCA is a well-characterized “chemical chaperone” that reduces ER stress, which is the same mechanism behind its neuroprotective research (ALS, Parkinson’s, Huntington’s). That shared mechanism is what prompted kidney-specific studies rather than any direct historical use of TUDCA in nephrology.
TUDCA and Acute Kidney Injury (Ischemia-Reperfusion Models)
Two independent research groups have tested TUDCA in models simulating acute kidney injury (AKI) from interrupted and restored blood flow — a common cause of AKI in hospitalized patients and after kidney transplant.
One study administered TUDCA in a rat ischemia-reperfusion model and found it reduced kidney injury markers, attributing the effect specifically to inhibition of ER stress pathways in renal tissue.[1] A second, separate study tested TUDCA in both a rat ischemia-reperfusion model and a human kidney cell culture model designed to simulate the stress kidneys experience during cold storage before transplant. TUDCA significantly reduced injury in both models, and the researchers linked this to inhibition of the mitochondrial apoptosis pathway along with upregulation of cell-survival signaling — concluding the results supported testing TUDCA in future human AKI prevention trials.[2] As of this writing, no such human trial has been published.
TUDCA and Diabetic Kidney Disease
Diabetic nephropathy is one of the leading causes of chronic kidney disease, and ER stress is implicated in the tubular and glomerular damage it causes. In a study using db/db mice (a standard type 2 diabetes model), animals treated with TUDCA by injection for eight weeks had significantly reduced blood glucose, reduced albuminuria (protein in the urine, a marker of kidney damage), and less renal tissue damage under microscopy compared to untreated diabetic mice. The kidneys of TUDCA-treated mice also showed fewer markers of ER-stress-driven cell death.[3]
A related but distinct study tested TUDCA as an add-on to telmisartan (a standard blood-pressure medication also used for kidney protection in diabetes) in a diabetic kidney disease model, finding the combination outperformed either treatment alone at restoring kidney function and reducing fibrotic and apoptotic signaling. This points toward TUDCA being studied as a complementary mechanism to existing kidney-protective drugs, not a replacement for them.
TUDCA and Salt-Induced Kidney Injury
A separate research thread has looked at chronic high-salt intake, which can drive kidney injury and inflammation, particularly in the presence of impaired endothelin B receptor function. In that model, TUDCA treatment abolished the increases in kidney injury markers, proteinuria, albuminuria, and inflammatory cell infiltration otherwise seen with a high-salt diet.[4] This is a specialized model rather than a general test of “high salt intake” in typical diets, and it has not been tested in humans.
Why This Is Still Preclinical Evidence
It’s worth being clear-eyed about what stage this research is at. Every study above was conducted in rodents or isolated human cells — not in human patients with kidney disease. Rodent kidney-injury models, however well-designed, do not always translate to human outcomes, and dosing in these studies (often delivered by injection rather than oral supplementation) does not map directly onto what an oral supplement dose would achieve in a person. The AKI researchers themselves explicitly framed their results as groundwork for future human trials, not a finished case for clinical use.[2]
People with chronic kidney disease, reduced kidney function, or on dialysis should be especially cautious about self-directed supplementation. Kidney disease management is highly individualized, and some supplements that seem “kidney-protective” in a lab model carry different risk profiles in people with already-impaired renal clearance. This is a conversation for a nephrologist, not a decision to make from animal-study abstracts.
Frequently Asked Questions
Does TUDCA protect the kidneys in humans?
There is no published human clinical trial testing TUDCA for kidney protection. All current evidence — in acute kidney injury, diabetic kidney disease, and salt-induced kidney injury — comes from rodent models and cell culture, not human patients.
Is TUDCA safe for people with chronic kidney disease?
This has not been specifically studied. People with chronic kidney disease or reduced renal function should talk to a nephrologist before taking TUDCA or any new supplement, since impaired kidney clearance can change how a compound is processed and tolerated.
How does TUDCA affect the kidneys mechanistically?
TUDCA’s kidney research centers on its ability to reduce endoplasmic reticulum (ER) stress, a cellular process implicated in acute kidney injury, diabetic nephropathy, and fibrosis. Reducing ER stress in animal models has been linked to reduced kidney tissue damage and lower markers of cell death.
Could TUDCA help with diabetic kidney disease?
Animal studies in diabetic mice show TUDCA reduced albuminuria and kidney damage, and one study found it improved outcomes when combined with a standard kidney-protective blood pressure medication. This has not been confirmed in human trials and should not be treated as a substitute for standard diabetic kidney disease management.
References
- The nephroprotective effect of tauroursodeoxycholic acid on ischaemia/reperfusion-induced acute kidney injury by inhibiting endoplasmic reticulum stress. Basic & Clinical Pharmacology & Toxicology (2012). PMID 22212133
- Prevention of acute kidney injury by tauroursodeoxycholic acid in rat and cell culture models. PLoS ONE (2012). PMID 23152827
- Tauroursodeoxycholic acid attenuates renal tubular injury in a mouse model of type 2 diabetes. Nutrients (2016). PMID 27669287
- Tauroursodeoxycholic acid (TUDCA) abolishes chronic high salt-induced renal injury and inflammation. Acta Physiologica (2019). PMID 30501003
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
